Skip to content
Screener

Insmed INSM Reportable Segment — Product revenues, net

Similar metrics at other companies

Collegium Pharmaceutical, Inc. logo
COLLSegment — Product revenues, net
$199.88M+6.3%
Vertex Pharmaceuticals logo
VRTXProduct revenues, net — Product revenues, net
$3.33B+13.2%
Vertex Pharmaceuticals logo
VRTXOther CF product revenues — Product revenues, net
$135.9M-12.5%
Vertex Pharmaceuticals logo
VRTXPharmaceuticals — Product revenues, net
$2.99B+7.8%
Vertex Pharmaceuticals logo
VRTXOther revenues — Product revenues, net
$0-100%
Vertex Pharmaceuticals logo
VRTXALYFTREK — Product revenues, net
$573.6M+266%

Other financials

Income statement

See full
Revenue$425.5M+296%
Gross profit$358.3M+352%
Operating income-$1.5M+99.5%
Net income-$13.2M+95.9%
EPS (diluted)-$0.06+96.5%

Balance sheet

See full
Cash & equivalents$544.8M-57.6%
Total debt$579.9M+0.8%
Total equity$757.5M-39.4%
Total assets$2.1B-15.2%

Cash flow

See full
Operating cash flow-$88.8M+56.8%
CapEx$6.3M+79.6%
Free cash flow-$95.1M+54.5%

Valuation

See full
Market cap$28.95B+37.0%
Enterprise value$28.98B+41.9%
P/S25.4×-27.6×

Profitability

See full
Gross margin83.5%+7.7pp
Operating margin-73.9%-30.6pp
Net margin-76.9%-31.8pp
FCF margin-71%-28.6pp

Returns & leverage

See full
Return on equity-87.2%-27.3pp
Debt / equity0.8×+0.3×
Current ratio3.7×-3.0×

Where this comes from

Reported directly by Insmed in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Insmed’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 6:59 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001104506-26-000041
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Product revenues, net$425,486$107,415$731,450$200,238
Less:
Cost of product revenues (excluding amortization of intangible assets)67,21228,075114,63249,353
TPIP external R&D expenses38,93520,64976,27629,802
Brensocatib external R&D expenses13,82933,56032,31354,221
ARIKAYCE external R&D expenses6,22811,00314,85023,124
Other external R&D expenses48,83628,44581,51456,528
R&D compensation and benefit-related expenses69,08056,389141,220109,947

Item 1C. Consolidated Financial Statements

FAQ

What is Insmed's reportable segment — product revenues, net?
Insmed (INSM) reported reportable segment — product revenues, net of $425.49M in Q2 2026.
How has Insmed's reportable segment — product revenues, net changed year-over-year?
Insmed's reportable segment — product revenues, net increased by 296.1% year-over-year, from $107.42M to $425.49M.
What is the long-term trend for Insmed's reportable segment — product revenues, net?
Over 3 years (2022 to 2025), Insmed's reportable segment — product revenues, net has grown at a 35.2% compound annual growth rate (CAGR), from $245.36M to $606.42M.
What does reportable segment — product revenues, net mean?
This represents the total revenue generated from the sale of commercial products after accounting for returns, allowances, and rebates. It serves as the primary indicator of market adoption and commercial success for the company's therapeutic portfolio.

Ask your AI about Insmed's reportable segment — product revenues, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude